MI-nc (hydrochloride)
目录号 : GC12173
A negative control for MI-2
Cas No.:1934302-23-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MI-nc is a weak inhibitor of the menin-MLL fusion protein interaction with an IC50 of 193 μM. It can be used as a negative control compound for tests involving MI-2, which showed more binding potency with menin, blocked the menin-MLL interaction with an IC50 of 0.45 μM, and induced apoptosis in cells expressing MLL fusion proteins [1].
Menin, a product of the multiple endocrine neoplasia gene, is an essential co-factor of oncogenic MLL fusion proteins. MLL interacts with menin in a bivalent mode involving 2 N-terminal fragments of MLL, and the menin–MLL interaction is critical for development of acute leukemia. Inhibition of the menin interaction with MLL fusion proteins is a very promising strategy to reverse their oncogenic activity [2].
References:
[1]. Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia[J]. Nature chemical biology, 2012, 8(3): 277-284.
[2]. Yokoyama A, Somervaille T C P, Smith K S, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis[J]. Cell, 2005, 123(2): 207-218.
| Cas No. | 1934302-23-4 | SDF | |
| 化学名 | 6-ethyl-4-[4-(1,3,4-thiadiazol-2-yl)-1-piperazinyl]-thieno[2,3-d]pyrimidine, dihydrochloride | ||
| Canonical SMILES | CCC(S1)=CC(C1=NC=N2)=C2N3CCN(C4=NN=CS4)CC3.Cl.Cl | ||
| 分子式 | C14H16N6S2 • 2HCl | 分子量 | 405.4 |
| 溶解度 | ≤0.1mg/ml in ethanol;1.3mg/ml in DMSO;0.5mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4667 mL | 12.3335 mL | 24.667 mL |
| 5 mM | 0.4933 mL | 2.4667 mL | 4.9334 mL |
| 10 mM | 0.2467 mL | 1.2333 mL | 2.4667 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。